NUPLAZID® (pimavanserin) logo - once daily - 34 mg capsules
NUPLAZID® (pimavanserin) logo - once daily - 34 mg capsules NUPLAZID® (pimavanserin) logo - once daily - 34 mg capsules

NUPLAZID® is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

Acadia Connect logo for patient, caregiver, and healthcare professional support website

Support for your practice and the families you care for

Acadia Connect® helps ensure that it’s easy for your patients or residents to start and continue taking NUPLAZID. We’re here to support you and those prescribed NUPLAZID with access, insurance, affordability, and prescription assistance.

Acadia Connect enrollment

Complete the Treatment & Service Request Form to prescribe NUPLAZID, request a free 14-day supply* (if applicable), and enroll your patient or resident in Acadia Connect. You can fill out the form online at acadiaconnect.com, or click the button below to download a PDF and submit via fax or email.

Download Treatment &
Service Request Form

*Appropriate patients must be enrolled in Acadia Connect to be eligible for the free 14-day supply. Acadia Connect patient eligibility and terms and conditions apply.

Your office will be paired with a Patient Access Manager (PAM) to assist you as your patients start and continue treatment.

Your patients will be assigned a dedicated Care Coordinator they can turn to for help with insurance coverage, financial assistance, and prescription delivery.

When prescribing NUPLAZID, please use one of these specialty pharmacies

Chart shows which in-network pharmacies provide pickup and which provide prescription delivery
Chart shows which in-network pharmacies provide pickup and which provide prescription delivery

Your patient’s prescription may be more affordable than you expect, thanks to the comprehensive coverage and financial assistance support Acadia Connect offers.

  • 9 in 10 patients pay less than $10 as final out-of-pocket costs for their prescription†

  • 100% of Medicare Part D plans cover NUPLAZID1

  • $0 co-pay for qualifying commercially covered patients‡

See prescription 
coverage options

†Around 10% of patients pay more than $10 for their prescription (as reported by 4 specialty pharmacy organizations; Q4 2020 and Q1 2021 data).

‡Acadia Connect patient eligibility and terms and conditions apply.

These simple tools were created to help you enroll your patients in Acadia Connect and get them started on their prescription medication.

Formulary lookup

See if your patient’s insurance will cover NUPLAZID.

Check coverage

This information is intended as a guide. Coverage and costs may differ between private and government insurance plans, and are subject to change. Please check with the health plan to confirm coverage for individual patients.

Prior authorization

Your patient may need authorization to get insurance coverage for NUPLAZID.

Start a request

Patient Access Manager tool

Your Patient Access Manager (PAM) can assist with access or affordability issues and keep you informed if there's an interruption to the treatment regimen you prescribed.

Find your PAM

Letter forms

Find templates in the event your patients need a letter of appeal or letter of medical necessity. You can also download PDF versions of the letter of appeal template and the letter of medical necessity template.

Create letters

Diagnostic codes for easy reference

Details on Parkinson’s disease (PD) psychosis ICD-10 codes

Here’s a quick list of what you need to know about ICD-10 codes for patients with PD-related hallucinations and delusions.

For diagnostic codes in treating PD psychosis§: Coding must be to the highest level of specificity.

All coding decisions are ultimately the responsibility of each prescribing healthcare provider.

Coding combinations recognized for PD psychosis include G20 (PD) plus one of the following ICD-10 codes2:

  • F06.0 Psychotic disorder with hallucinations due to known physiological condition

  • F06.2 Psychotic disorder with delusions due to known physiological condition

§Diagnostic codes are not required to complete the NUPLAZID treatment form.

Questions? Connect with an Acadia Connect representative.

1-844-737-2223
Monday through Friday
8:00 AM-8:00 PM ET

Get helpful resources from Acadia Connect for you and your patients.

Browse resources
Real‐World Evidence
Resource Library

IMPORTANT SAFETY INFORMATION and INDICATION

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
  • NUPLAZID is not approved for the treatment of patients with dementia who experience psychosis unless their hallucinations and delusions are related to Parkinson’s disease.
  • Contraindication: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.

  • Warnings and Precautions: QT Interval Prolongation

    • NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval (e.g., Class 1A antiarrhythmics, Class 3 antiarrhythmics, certain antipsychotics or antibiotics).

    • NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.

  • Adverse Reactions: The adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).

  • Drug Interactions:

    • Coadministration with strong CYP3A4 inhibitors increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily.

    • Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID.

Indication NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

Dosage and Administration Recommended dose: 34 mg capsule taken orally once daily, without titration, with or without food.

NUPLAZID is available as 34 mg capsules and 10 mg tablets.

Please read the full Prescribing Information, including Boxed WARNING.

References:
  1. Managed Markets Insight & Technology. Formulary Lookup website. https://formularylookup.com. Accessed August 4, 2020.
  2. Centers for Medicare & Medicaid Services. ICD-10-CM Tabular List of Diseases and Injuries. US Department of Health and Human Services; 2020.

Safety & Tolerability